CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at the American Epilepsy Society (AES) 70^th Annual Meeting, taking place December 2-6, 2016 in Houston, TX. Members of the company's medical affairs team will be accessible at booth number 918.

Below is the schedule for the presentations and a Sage-sponsored scientific exhibit:

Date: Saturday, December 3, 2016
Poster Presentation Time: 12:00 p.m. - 6:00 p.m. CT
Location: Hall A3/Level 3, George R. Brown Convention Center
Poster Number: 1.261
Title: SAGE-217, a next generation neuroactive steroid positive allosteric modulator of synaptic and extra-synaptic GABA_A receptors, is active against audiogenic seizures in Fmr1 knockout mice

Date: Sunday, December 4, 2016
Poster Presentation Time: 10:00 a.m. - 4:00 p.m. CT
Location: Hall A3/Level 3, George R. Brown Convention Center
Poster Number: 2.187
Title: SGE-516, a next generation neuroactive steroid, reduces status epilepticus (SE) after a 20 or 40-minute treatment delay in a rat model of soman intoxication

Date: Sunday, December 4, 2016
Poster Presentation Time: 10:00 a.m. - 4:00 p.m. CT
Location: Hall A3/Level 3, George R. Brown Convention Center
Poster Number: 2.185
Title: SAGE-689, a potent and selective next generation neuroactive steroid, reduces electrographic seizure activity in a rat model of pharmacoresistant status epilepticus while phenytoin does not

Date: Sunday, December 4, 2016
Sage Sponsored Scientific Exhibit Time: 2 p.m. - 5 p.m. CT
Location: Room 360 AD
Title: Neuroactive Steroids in the Treatment of GABA_A-Related Disorders.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161201006314/en/

Investor Contact:
Sage Therapeutics
Paul Cox, 617-299-8377
paul.cox@sagerx.com
or
Media Contact:
Suda Communications LLC
Maureen L. Suda, 585-387-9248
maureen.suda@sagerx.com

Source: Sage Therapeutics

News Provided by Acquire Media